PTEN's Evolving Role in Prostate Cancer Care
- PTEN loss is one of the most common tumor suppressor alterations in prostate cancer, occurring in approximately 15-20% of localized disease and up to 40-50% of metastatic castration-resistant prostate cancer (mCRPC).
- Its biological consequences are profound, influencing tumor growth, treatment resistance, and clinical outcomes.
- PTEN loss has been shown to “identify a pathway that is targetable” and clearly identify “a subset of patients that will do poorly with current standards of treatment,” Dr. Stephen Freedland, a urologist at Cedars-Sinai, says.
- From a clinical perspective, Dr. Freedland emphasizes that the extent of loss matters. Tumors with widespread PTEN loss (e.g., near-complete absence across tumor cells) behave significantly more aggressively than those with partial or heterogeneous loss.
Over the past decade, our understanding of prostate cancer biology has shifted from a largely clinicopathologic framework to one increasingly driven by molecular alterations. Among these, loss of the tumor suppressor gene PTEN has emerged as one of the most consistent genomic events.
PTEN loss is one of the most common tumor suppressor alterations in prostate cancer, occurring in approximately 15-20% of localized disease and up to 40-50% of metastatic castration-resistant prostate cancer (mCRPC). Its biological consequences are profound, influencing tumor growth, treatment resistance, and clinical outcomes.
“PTEN is a protein that most cells have … It basically helps stop the cell from growing and dividing. Unfortunately in cancer cells, sometimes that gene that makes that protein is lost — and we call this PTEN loss,” Dr. Stephen Freedland, a urologist at Cedars-Sinai, tells SurvivorNet Connect.
While PTEN’s role when it comes to treatment planning for prostate cancer is still evolving, Dr. Freedland says, there is evidence that it can help identify patients who are unlikely to respond well to current treatment standards, particularly among patients with advanced disease.
The Biology of PTEN: A Central Tumor Suppressor
PTEN is a dual-specificity phosphatase that plays a central role in regulating the PI3K/AKT/mTOR signaling axis. Under normal conditions, PTEN antagonizes PI3K activity by converting PIP3 back to PIP2, thereby preventing downstream activation of AKT and mTOR pathways.
“When you lost a tumor suppressor gene, you get activation of other pathways, PI3K being one, AKT being one, and we have data that you can target AKT with small molecules,” Dr. Freedland explains.
“There was a completed phase III trial, showed some evidence of benefits. Whether this will may be approved by the FDA, [and] used in patients, we’re still waiting to see,” he adds. “But it’s at least proof of principle that PTEN loss does identify a pathway that is targetable and also clearly identifies a subset of patients that will do poorly with current standards of treatment.”
Loss of PTEN (whether through genomic deletion, mutation, or epigenetic silencing) results in unchecked activation of this signaling cascade. The downstream effects are extensive:
- Increased cellular proliferation
- Enhanced survival signaling (anti-apoptotic effects)
- Altered metabolism
- Increased invasiveness and metastatic potential
These biological changes explain why PTEN loss is consistently associated with adverse pathological features and poor oncologic outcomes.
PTEN Loss and Tumor Growth
One of the most clinically relevant aspects of PTEN loss is its strong association with aggressive disease biology.
Patients with PTEN-deficient tumors are more likely to present with:
- Higher Gleason grade
- Advanced stage disease
- Increased risk of biochemical recurrence
- Earlier metastasis
- Shorter cancer-specific survival
These findings are highly reproducible across studies and have established PTEN as a robust prognostic biomarker.
“We actually see, particularly in patients with higher risk disease metastasis at diagnosis, a number of these patients, these tumors have lost PTEN,” Dr. Freedland explains. “What it tells us is that those tumors are going to be more aggressive, going to grow faster and be more resistant to our standard treatments.”
From a clinical perspective, Dr. Freedland emphasizes that the extent of loss matters. Tumors with widespread PTEN loss (e.g., near-complete absence across tumor cells) behave significantly more aggressively than those with partial or heterogeneous loss.
This intratumoral heterogeneity also creates diagnostic challenges, particularly in biopsy specimens, where focal loss may be missed.
CAPItello-281 and the Role of Capivasertib
The phase III CAPItello-281 trial represents a major step forward in translating PTEN biology into clinical action.
In this study, patients with PTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC) were treated with the AKT inhibitor capivasertib (brand name Truqap) in combination with abiraterone and androgen deprivation therapy.
The results were clinically meaningful:
- Median rPFS: 33.2 months vs. 25.7 months
- Hazard ratio: 0.81
- Statistical significance: p = 0.034
Importantly, the benefit appeared more pronounced as the degree of PTEN loss increased, reinforcing the biologic importance of this pathway.
Mechanistically, this trial confirms a critical concept: AR blockade alone is insufficient in PTEN-deficient disease. The PI3K/AKT pathway provides an alternative survival signal, allowing tumor progression despite hormonal therapy.
However, toxicity is an important consideration.
The addition of capivasertib was associated with:
- Diarrhea
- Hyperglycemia
- Rash
These adverse events were manageable but require close monitoring and dose adjustments in clinical practice.
From a clinical perspective, Dr. Freedland frames these findings as a critical step forward, but not yet a paradigm shift.
“PTEN loss identifies a pathway we can target,” he explains. “Now the question is how do we build on that and improve outcomes further. We’re not at a place where we recommend testing PTEN on every newly diagnosed prostate cancer patient, but for those with metastatic disease, late stage disease, testing for PTEN can identify [disease] that’s going to act more aggressively.”
“I always say, ‘aggressive disease needs aggressive therapy,'” Dr. Freedland adds.
Why This Matters Now
PTEN is a clear example of how oncology is evolving, from population-based treatment to biology-driven care.
For decades, prostate cancer management relied on:
- PSA
- Gleason score
- Clinical stage
These remain essential, but there are more factors to consider.
“What we’re realizing is that our current clinical tools are not strong enough to identify the most aggressive tumors. That’s where biomarkers like PTEN come in,” Dr. Freedland says.
This becomes even more important as innovative therapies move earlier in the disease course. The challenge is identifying which patients truly need treatment intensification. PTEN may help define that group.
At the same time, it may help avoid overtreatment in others. That dual role is at the heart of precision oncology.
